...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pediatrics: Official Publication of the American Academy of Pediatrics >Delayed-Onset of Multiple Cutaneous Infantile Hemangiomas Due to Propranolol: A Case Report
【24h】

Delayed-Onset of Multiple Cutaneous Infantile Hemangiomas Due to Propranolol: A Case Report

机译：普萘洛尔引起的多发性婴幼儿皮肤血管瘤延迟发作：一例报告

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Infantile hemangiomas are the most common vascular tumors in childhood. In view of its proven effectiveness in such cases, propranolol is the drug of choice. We present the case of a male infant who started treatment with propranolol shortly after birth due to heart disease. After 7 months, when the patient had suffered various respiratory exacerbations, this treatment was suspended. One week later, multiple skin lesions (ie, multifocal infantile hemangiomas) began to appear, with no extracutaneous involvement. It was decided to resume treatment with propranolol, although at lower doses than before, and the skin lesions improved rapidly, with some disappearing completely. Treatment was definitively withdrawn at age 16 months, with only slight recurrence of the lesions. The case described is of multifocal infantile hemangiomas without extracutaneous involvement appearing beyond the neonatal period after treatment with propranolol beginning in the first days of life. The details of the case support the hypothesis that this drug is not only therapeutic but also plays a prophylactic role against infantile hemangiomas. In turn, this supports the recent proposal that this drug may be useful in preventing the growth and spread of tumors with high angiogenic potential. It is postulated that the inhibition of beta-adrenergic receptors is associated with multiple intracellular processes related to the progression and metastasis of different tumors.
机译：小儿血管瘤是儿童时期最常见的血管肿瘤。考虑到在这种情况下已证明的有效性，普萘洛尔是首选药物。我们介绍了一例男婴，他因心脏病在出生后不久就开始使用普萘洛尔治疗。 7个月后，当患者遭受各种呼吸恶化时，该治疗被暂停。一周后，开始出现多处皮肤病变（即多灶性婴幼儿血管瘤），而无皮外累及。决定恢复使用普萘洛尔的治疗方法，尽管剂量比以前低，并且皮肤病变迅速改善，有些完全消失。在16个月大时明确撤出治疗，仅轻微复发病变。所描述的病例是多发性婴儿血管瘤，在生命的第一天开始使用普萘洛尔治疗后，在新生儿期之后未出现皮外累及。案件的详细情况支持以下假设：该药不仅具有治疗作用，而且还可以预防婴儿血管瘤。反过来，这支持了最近的提议，即该药物可用于预防具有高血管生成潜力的肿瘤的生长和扩散。据推测，β-肾上腺素受体的抑制与与不同肿瘤的进展和转移有关的多个细胞内过程有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号